When diagnosing lung metastases and second primary lung cancer in patients with head and neck cancer, low-dose CT leads to better sensitivity than chest x-ray but does not lead to improved overall ...

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

A new systemic nutrition-inflammation index predicted perioperative non-small cell lung cancer outcomes better than current ...

The novel therapy is anticipated to function like PD-1/PD-L1 blockade with significant clinical efficacy results in ...

Cancer impacts millions globally, with lifestyle choices such as smoking, diet, physical activity, alcohol consumption, sun ...

China NMPA approves Akeso's penpulimab for first-line treatment of nasopharyngeal cancer: Hong Kong Tuesday, March 18, 2025, 17:00 Hrs [IST] Akeso Inc., a biopharmaceutical compan ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...

Chen, F. (2025) Advances in the Application of Deep Learning in Prognostic Models for Non-Small Cell Lung Cancer. Health, 17, ...

Small-cell lung cancer is a highly malignant form of lung cancer, also known as oat-cell carcinoma, that accounts for approximately 15% of lung cancer cases. Composed of small, ovoid cells with ...

Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC ... c-Met-positive, non-squamous NSCLC as a second ...